Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The Hazards of Hazardous Drug Labeling: Time to Revisit Hydroxyurea?
source: The Hematologist
year: 2019
authors: Andrea Cervi, MD, MSc; Artemis Diamantouros, BScPhm, MEd, PhD; Madeleine Verhovsek, MD, FRCPC
summary/abstract:Despite benefits in reducing pain crises, transfusions, hospitalizations, and mortality in sickle cell disease (SCD),1-5 hydroxyurea (HU) is underutilized.1,6,7 A recent Cochrane meta-analysis found no significant increase in adverse events among HU-treated patients with SCD,8 yet fears of possible adverse effects have been identified as a key barrier to HU acceptance.9-11 In light of the poor uptake of HU among the SCD population, hematologists need to fully understand patient and provider reluctance about this disease-modifying therapy.
organization: McMaster University, Canada; University of Toronto, Canadafull text
+myBinderRelated Content
-
Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activ...Sickle cell anemia is a manifestation of...
-
New Method of Creating Healthy Stem Cells Could Potentially Improve Treatment of Sickle Cell AnemiaResearchers at New York’s Weill Cornel...
-
First systemic evidence for safety of tPA in stroke patients with sickle cell diseaseIn the largest report on acute stroke in...
-
FDA Approves Hydroxyurea Tablets for Pediatric Patients With Sickle Cell AnemiaThe US Food and Drug Administration (FDA...
-
Haematopoietic stem cell transplantation for sickle cell disease – current practice and new approachesSickle cell disease is an inherited diso...
-
New Sickle Cell Disease Research Shows Improved Patient OutcomesEmerging therapies and promising new ins...
-
Sickle Cell Anemia Toddlers Benefit from Maximal Hydroxyurea Doses, Study FindsIntensifying treatment with hydroxyurea ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.